Education
About Us
Working with TipRanks
Follow Us
Helix BioPharma (TSE:HBP)
TSX:HBP
HBP Stock Chart & Stats
C$2.40
-C$0.03(-3.23%)
At close: 4:00 PM EST
C$2.40
-C$0.03(-3.23%)
Day’s Range― - ―
52-Week RangeC$0.75 - C$5.40
Previous CloseN/A
Volume518.00
Average Volume (3M)13.00K
Market Cap
C$140.54M
Enterprise ValueC$130.17M
Total Cash (Recent Filing)C$31.00K
Total Debt (Recent Filing)C$359.00K
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Equity BaseVery low debt (TTM D/E ~0.02) and a meaningful equity cushion reduce near-term solvency risk and give management financing flexibility. This durable balance-sheet strength helps sustain clinical programs and supports partnering or licensing discussions without immediate heavy interest burden.
Focused Oncology R&D And Licensing PathwayA clear strategic focus on oncology therapeutics aligns with persistent structural demand and high partner interest. As a clinical-stage company, monetization via out-licensing, co-development, or milestone/royalty deals is a durable path that can generate non-dilutive or value-accretive funding if clinical progress continues.
Improving Loss Trend / Cost TighteningReported losses have narrowed versus prior years, indicating effective cost controls and tighter spending. Sustained expense discipline can extend runway, reduce near-term financing needs and enable management to prioritize highest-value trials, improving long-term viability absent immediate revenue.
Bears Say
No Revenue GenerationThe company reports no commercial revenue and ongoing negative gross profits, meaning it remains fully pre-revenue. Without product sales, Helix must rely on external financing or partnerships; this structural absence of operating revenue increases execution risk and likelihood of dilution until approval or deal monetization occurs.
Persistent Cash Burn And Weak FCFConsistent negative operating and free cash flow (~-$3.7M TTM) creates an ongoing funding requirement. Even with some historical improvement, deterioration versus certain annual periods shows runway vulnerability; sustained burn forces repeat financing rounds or asset sales, which can limit strategic choices.
Historical Balance Sheet VolatilityPast episodes of negative equity and capitalization swings signal recurring losses and financing stress. This history of balance-sheet volatility can undermine partner confidence, make large collaborations harder to secure, and represents a structural governance and funding risk over the next several months.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.75 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$140.54M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Jun 17, 2026 which is in 90 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Mar 16, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.793%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---